Michael Møller‐Hansen

Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease

Michael Møller‐Hansen, Ann‐Cathrine Larsen, Peter Bjerre Toft et al. · The Ocular Surface · 2020 · 82 citations

Medicine, Ophthalmology, Surgery +14

Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II)

Charlotte Duch Lynggaard, Christian Grønhøj, Robin Christensen et al. · Stem Cells Translational Medicine · 2022 · 43 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sjögren's syndrome: A randomized clinical trial

Michael Møller‐Hansen, Ann‐Cathrine Larsen, Anne Katrine Wiencke et al. · The Ocular Surface · 2023 · 42 citations

Medicine, Immunology, Ophthalmology +16

CIED infection with either pocket or systemic infection presentation – complete device removal and long-term antibiotic treatment; long-term outcome

Nikolaj Ihlemann, Michael Møller‐Hansen, Kirsten Salado-Rasmussen et al. · Scandinavian Cardiovascular Journal · 2015 · 12 citations

Medicine, Infectious Diseases, Surgery +15

Intraglandular mesenchymal stem cell treatment induces changes in the salivary proteome of irradiated patients

Charlotte Duch Lynggaard, Rosa Jersie-Christensen, Morten Juhl et al. · Communications Medicine · 2022 · 11 citations · Full text

Dentistry, Oncology, Oral Biology +17